Related Experiment Video
Updated: Jul 2, 2025

Author Spotlight: Decoding RNA Methylation's Role in Pancreatic Cancer - A Single-Base Resolution Study
Published on: July 7, 2023
M6A RNA methylation in biliary tract cancer: the function roles and potential therapeutic implications
Xuesong Bai1, Jianhao Huang1, Yiqun Jin2
1Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Abstract:
Biliary tract cancers (BTCs) are relatively rare malignancies with a poor prognosis. For advanced BTCs, the efficacy of current chemotherapeutic approaches is limited. Consequently, there is an urgent need to deepen our understanding of the molecular mechanisms underlying BTC tumorigenesis and development for the exploration of effective targeted therapies. N6-methyladenosine (m6A), the most abundant RNA modifications in eukaryotes, is found usually dysregulated and involved in tumorigenesis, progression, and drug resistance in tumors. Numerous studies have confirmed that aberrant m6A regulators function as either oncogenes or tumor suppressors in BTCs by the reversible regulation of RNA metabolism, including splicing, export, degradation and translation. In this review, we summarized the current roles of the m6A regulators and their functional impacts on RNA fate in BTCs. The improved understanding of m6A modification in BTCs also provides a reasonable outlook for the exploration of new diagnostic strategies and efficient therapeutic targets.
Insights
N6-methyladenosine (m6A) regulators are crucial in biliary tract cancers (BTCs), influencing tumor development and drug resistance. Understanding these m6A alterations offers new avenues for targeted therapies and diagnostics in BTC.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Biliary tract cancers (BTCs) are rare with poor prognoses, and current treatments for advanced stages are limited.
- Understanding BTC molecular mechanisms is vital for developing effective targeted therapies.
- N6-methyladenosine (m6A) is the most common RNA modification, often dysregulated in cancers.
Purpose of the Study:
- To review the roles of m6A regulators in BTC tumorigenesis and progression.
- To explore the functional impacts of m6A regulators on RNA metabolism in BTCs.
- To highlight the potential of m6A modification as a target for novel BTC diagnostics and therapeutics.
Main Methods:
- Literature review of studies on m6A regulators in BTC.
- Analysis of m6A regulator functions in RNA processing (splicing, export, degradation, translation).
- Synthesis of current knowledge on m6A's role in BTC development and drug resistance.
Main Results:
- Aberrant m6A regulators act as oncogenes or tumor suppressors in BTC.
- m6A modification influences RNA metabolism, impacting cancer progression.
- Dysregulated m6A pathways are implicated in BTC tumorigenesis and therapeutic resistance.
Conclusions:
- m6A regulators play significant roles in BTC pathogenesis.
- Targeting m6A pathways presents a promising strategy for BTC treatment.
- Further research into m6A modifications could lead to improved diagnostic and therapeutic approaches for BTC.
Related Concept Videos
Epigenetic Regulation
MicroRNAs
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
RNA Stability
Master Transcription Regulators

